
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 April 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 5MB, 226 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
“Angiotensin converting enzyme inhibitors and hepatocellular carcinoma incidence in the General Practice Research Database”, Cancer Causes Control, vol. 22, pp. 1743-7, 2011.
, “Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study”, Br J Cancer, vol. 107, pp. 1602-7, 2012.
, , “Can granulomatosis with polyangiitis be diagnosed earlier in primary care? A case-control study”, Qjm, vol. 111, pp. 39-45, 2018.
, “Comorbidities in patients with gout prior to and following diagnosis: case-control study”, Ann Rheum Dis, vol. 75, pp. 210-7, 2016.
, “Correction to: The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink”, Clin Rheumatol, vol. 37, p. 2601, 2018.
, “Development and validation of risk prediction model for venous thromboembolism in postpartum women: multinational cohort study”, Bmj, vol. 355, p. i6253, 2016.
, “Disease Activity in Inflammatory Bowel Disease Is Associated With Arterial Vascular Disease”, Inflamm Bowel Dis, 2020.
, “Early Clinical Features in Systemic Lupus Erythematosus: Can They Be Used to Achieve Earlier Diagnosis? A Risk Prediction Model”, Arthritis Care Res (Hoboken), vol. 69, pp. 833-841, 2017.
, “Effect of allopurinol on all-cause mortality in adults with incident gout: propensity score-matched landmark analysis”, Rheumatology (Oxford), vol. 54, pp. 2145-50, 2015.
, , “Impact of gout on the risk of atrial fibrillation”, Rheumatology (Oxford), vol. 55, pp. 721-8, 2016.
, “The incidence of first venous thromboembolism in and around pregnancy using linked primary and secondary care data: a population based cohort study from England and comparative meta-analysis”, PLoS One, vol. 8, p. e70310, 2013.
, “Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases”, Eur J Cancer, vol. 49, pp. 1404-13, 2013.
, “The incidence, prevalence and mortality of granulomatosis with polyangiitis in the UK Clinical Practice Research Datalink”, Rheumatology (Oxford), vol. 56, pp. 589-596, 2017.
, “The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink”, Clin Rheumatol, vol. 37, pp. 2103-2111, 2018.
, “Mortality in systemic lupus erythematosus in the United Kingdom 1999-2012”, Rheumatology (Oxford), vol. 55, pp. 854-60, 2016.
, “Novel insights into the aetiology of granulomatosis with polyangiitis-a case-control study using the Clinical Practice Research Datalink”, Rheumatology (Oxford), vol. 57, pp. 1002-1010, 2018.
, “Predictors and temporal trend of flu vaccination in auto-immune rheumatic diseases in the UK: a nationwide prospective cohort study”, Rheumatology (Oxford), vol. 57, pp. 1726-1734, 2018.
, “Recurrence risk of venous thromboembolism and hormone use in women from England: a cohort study using clinical practice research datalink”, Br J Haematol, vol. 177, pp. 127-135, 2017.
, “Rheumatoid arthritis and excess mortality: down but not out. A primary care cohort study using data from Clinical Practice Research Datalink”, Rheumatology (Oxford), vol. 57, pp. 977-981, 2018.
, “Rheumatoid arthritis is getting less frequent-results of a nationwide population-based cohort study”, Rheumatology (Oxford), vol. 56, pp. 736-744, 2017.
, “Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study”, Ann Rheum Dis, vol. 74, pp. 661-7, 2015.
, “Risk of first venous thromboembolism in pregnant women in hospital: population based cohort study from England”, Bmj, vol. 347, p. f6099, 2013.
, “The risk of venous thromboembolism during and after hospitalisation in patients with inflammatory bowel disease activity”, Aliment Pharmacol Ther, vol. 48, pp. 1099-1108, 2018.
, “Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data”, Br J Cancer, vol. 115, pp. 115-21, 2016.
, “Variation in the risk of venous thromboembolism in people with colorectal cancer: a population-based cohort study from England”, J Thromb Haemost, vol. 12, pp. 641-9, 2014.
, “Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis”, BMC Cancer, vol. 17, p. 747, 2017.
, “What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?”, Rheumatology (Oxford), 2021.
, “When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data”, Blood, vol. 127, pp. 849-57; quiz 953, 2016.
,